a97448d4-418a-4e9c-bd75-c4d217c20c89
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 86.9979466119097
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.380
- CHOLESTEROL_HOMEOSTASIS+0.350
- TNFA_SIGNALING_VIA_NFKB+0.350
- XENOBIOTIC_METABOLISM+0.330
- P53_PATHWAY+0.320
- COAGULATION+0.310
- APICAL_JUNCTION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- ANGIOGENESIS+0.270
- ADIPOGENESIS+0.260
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.450
- MITOTIC_SPINDLE-0.350
- UV_RESPONSE_DN-0.200
- MYC_TARGETS_V1-0.190
- PROTEIN_SECRETION-0.170
- SPERMATOGENESIS-0.170
- ANDROGEN_RESPONSE-0.140
- PANCREAS_BETA_CELLS-0.090
- HEME_METABOLISM-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290885 | — | — | 0.908 |
| 2 | SRR3147740 | — | — | 0.896 |
| 3 | BS_W7FP2G3F | DNET | — | 0.890 |
| 4 | BS_EFEZB0ZH | low-grade glioma | — | 0.872 |
| 5 | BS_T3H5AY8A | low-grade glioma | — | 0.869 |
| 6 | BS_C51RB0YR | low-grade glioma | — | 0.869 |
| 7 | BS_9BJARSX3 | pleomorphic xanthoastrocytoma(PXA) | — | 0.866 |
| 8 | MNG1110 | — | — | 0.865 |
| 9 | BS_YCREDZTJ | low-grade glioma | — | 0.860 |
| 10 | BS_77CDMEY4 | Ganglioglioma | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |